Table 1:

Characteristics and results of the cases with diffuse astrocytoma MYB/MYBL1–altered or angiocentric glioma, CNS WHO grade 1

Case	Age (yr)	Subgroup	Fusion/Methylation Analysis	T2-FLAIR Mismatch Sign (S) or Area (A)	Histology
Case	Age (yr)	Subgroup	Fusion/Methylation Analysis	T2-FLAIR Mismatch Sign (S) or Area (A)	Microcysts	Enlarged Intercellular Spaces
1	1.1	Diffuse Astro.	MYBL1::MMP16	+ (A)	–	–
2	3.2	Diffuse Astro.	MYBL1::STAU2-AS1	+ (S)	–	–
3	9.7	Diffuse Astro.	MYBL1::PACRG	+ (S)	+	+
4	9.0	Angio-centric glioma	No fusion analysis^{^a}	+ (A)	–	+
5	3.9	Diffuse Astro.	MYBL1::TOX	+ (S)	+	+
6	11.4	Diffuse Astro.	No fusion analysis, diagnosis based on methylome profile	+ (A)	–	+
7	4.4	Diffuse Astro.	No fusion analysis^{^a}	+ (A)	–	+
8	15.9	Angio-centric glioma	MYB::QKI	–	–	–
9	5.7	Diffuse Astro.	No fusion analysis^{^a}	–	–	+
10	9.6	Diffuse Astro.	No fusion analysis^{^a}	–	–	+
11	8.2	Angio-centric glioma	MYB::QKI	+ (A)	–	–

Note:—The + indicates presence; −, absence of the characteristic; Astro. astrocytoma.
↵a In case no fusion analysis was available, the diagnosis of diffuse astrocytoma, MYB- or MYBL1–altered or angiocentric glioma was based on results of histology in combination with methylome profiling using the Infinium MethylationEPIC (850k) BeadChip (Illumina, San Diego, CA) methylation array.